FDA-approved anti-PD-L1 drugs and CDx for NSCLC treatment
| Drugs | Anti-PD-L1 antibody | Stratifiation (biomarker scoring) | Fraction of biomarker positive | Clinical trial |
|---|---|---|---|---|
| Pembrorizumab | 22C3-pharmDx (Dako) | TPS < 1%: PD-L1 negative1% ≤ TPS < 50%: PD-L1 positiveTPS ≥ 50%: PD-L1 positive | 1% ≤ TPS < 50%: 37.6%TPS ≥ 50%: 23.2% | KEYNOTE-001 [29] |
| Nivolumab | 28-8-pharmDx (Dako) | Expression < 1%: PD-L1 negativeExpression ≥ 1%: PD-L1 positive | Expression ≥ 1%: 45.6% | CheckMate 227 [30] |
| Atezolizumab | SP142 (VENTANA) | TC, IC < 1%: PD-L1 negativeTC or IC ≥ 1%: PD-L1 positive | TC or IC ≥ 1%: 54.9% | OAK [31] |
TPS: tumor proportion score (fraction of PD-L1 expressing tumor cells); TC: fraction of PD-L1 expressing cells in the total tumor cells; IC: fraction of PD-L1 expressing cells in tumor infiltrating immune cells; OAK: atezolizumab vs. docetaxel in patients with previously treated non-small-cell lung cancer
